Wednesday, March 20, 2019 The MAX.1/LATTE - Long term Anastrozole vs Tamoxifen Treatment Effects (LATTE) trial was closed to further activity in Canada as of January 21, 2019. The lead group for this study, The Queen Mary University of London, Wolfson Institute of Preventive Medicine, Centre for Cancer Prevention announced in December 2018 that the study had met a key milestone of 15 years median follow-up of patients who were randomised to the monotherapy arms in the ATAC trial. Through the dedication of MAX.1/LATTE sites in the UK and internationally, nearly 3000 women completed 10 years of follow-up. At this milestone, the lead group reviewed their plans for the long-term collection of data and looked at the most efficient way to continue to meet the scientific objectives of the study. The study will continue in the UK via digital registries only, closing all UK and international sites before August 2019. The CRC4 (ECOG E5204) - Intergroup Randomized Phase III Study of Postoperative Oxaliplatin, 5-Fluorouracil and Leucovorin vs Oxaliplatin, 5-Fluorouracil, Leucovorin and Bevacizumab for Patients with Stage II or III Rectal Cancer Receiving Pre-Operative trial has been permanently closed and no further ethics approvals or folow up data is required. The notification of permanent trial closure has been the trial page as well as on the CCTG website under the "Toolbox" here: https://www.ctg.queensu.ca/trials/permanent_closure/permanent-trial-closure/ The trial objective was to compare the overall survival of patients with clinical Stage II and III rectal cancer who received preoperative chemoradiation and were treated with oxaliplatin leucovorin, 5-FU with or without bevacizumab postoperatively.
